Despite treatment advances in prostate cancer, it is associated with approximately 79,000 deaths in Europe and 34,000 deaths in the USA each year, presenting a clear unmet need.1,2 Most patients with metastatic castration-resistant prostate cancer (mCRPC) are ≥ 70 years of age and the median age of those who die from the disease is 80 years.3,4 Older patients with prostate cancer often have a complex clinical profile with comorbidities and functional and cognitive limitations.3,5 Furthermore, although several treatment options are available for patients with mCRPC, the optimal treatment sequence is still unclear. Consequently, in daily clinical practice, this presents clinicians with the challenge of selecting the appropriate treatments and sequence that will both increase survival outcomes and have acceptable safety profiles.